#France #Vorasidenib #Suresnes #VORANIGO #Prix Galien

Voranigo® (Vorasidenib) Achieves Notable Recognition

In an impressive showcase of innovation and dedication to improving patient outcomes, Voranigo® (vorasidenib), a treatment developed by Servier, has been awarded the esteemed Prix Galien accolades in a variety of geographic regions. This recognition highlights the importance of accessible and effective therapies for individuals diagnosed with rare and orphan diseases, particularly gliomas.

Recently, Voranigo® was honored with the Prix Galien USA award in the category of Best Product for Orphan/Rare Diseases, as well as the Prix Galien Poland award, and more recently, the prestigious Prix Galien Bridges 2025 award, presented during a ceremony in Stockholm. These awards signify not only the remarkable innovation behind Voranigo® but also its successful penetration and acceptance in diverse markets, including the Nordic countries, Austria, Israel, the Netherlands, Portugal, and Spain.

The Prix Galien awards are considered one of the highest honors in the field of biomedical research. They recognize exceptional advancements in pharmaceutical products, biotechnology, medical technology, and digital health. Arnaud Lallouette, Executive Vice President of Global Medical Affairs and Patient Engagement at Servier, expressed his gratitude for these recognitions, emphasizing their importance in marking the scientific progress that Voranigo® brings to patients suffering from glioma around the globe. “We are truly honored to receive these prestigious awards across multiple countries,” he stated, “Acknowledging our commitment to innovation and patient-centered care as we propel precision oncology forward for all who benefit from it.”

What is Voranigo®?

Voranigo® is designed to target grade 2 astrocytomas or oligodendrogliomas, particularly in patients who harbor the isocitrate dehydrogenase-1 (IDH1) R132 or isocitrate dehydrogenase-2 (IDH2) R172 mutations. It has been authorized for commercial sale in numerous countries, including the United States, Canada, Australia, Israel, the United Arab Emirates, Saudi Arabia, Switzerland, Brazil, the United Kingdom, Japan, and across 27 countries within Europe, allowing it to address the needs of adult patients and adolescents aged 12 and above. This treatment option is specifically for individuals who have undergone surgical intervention and do not require immediate radiotherapy or chemotherapy.

The recognition of Voranigo® through the Prix Galien awards exemplifies Servier’s mission to develop accessible treatments for those diagnosed with debilitating diseases, emphasizing the company's ongoing commitment to research and innovation in the pharmaceutical sector. Furthermore, it sheds light on the essential collaboration with biopharmaceutical communities across Europe and the Middle East, aiming to create a more interconnected network of healthcare solutions aimed at combating rare conditions.

As the healthcare landscape continues to evolve, Voranigo® stands as a testament to the potential of innovative therapies in improving the quality of life for patients battling rare diseases like glioma. Servier’s efforts in developing such targeted treatments underline the significance of ongoing research in the pharmaceutical industry, paving the way for future breakthroughs that hold the promise of enhanced patient care worldwide.

The journey of Voranigo® reflects the progress made in precision oncology, reinforcing the belief that with continued innovation, there is hope for patients in need.

For more information about Servier and Voranigo®, visit servier.com and stay updated with their latest advancements via social media platforms including LinkedIn, Facebook, X, and Instagram.